The management of melanoma is constantly evolving. New therapies and surgical advances have changed the landscape over the last years. Since being introcuced by Dr Donald Morton, the role of sentinel lymph node has been debated. In many melanoma centres, sentinel node biopsy is not a standard of care for melanoma above 1 mm in thickness. The results of the MSLT-II trial are not available for a while and in the meantime, this procedure is offered as a prognostic indicator as it has been shown to be very useful for assessing risk of relapse. The biology of lymph node spread in melanoma is a complex field and there are many factors which influence it such as age, melanoma body site, thickness but other factors such as regression, ulceration and gender need further evaluation.
Ribero, S., Sportoletti Baduel, E., Osella Abate, S., Dika, E., Quaglino, P., Picciotto, F., et al. (2017). Sentinel lymph node biopsy in cutaneous melanoma. GIORNALE ITALIANO DI DERMATOLOGIA E VENEREOLOGIA, 152(4), 355-359 [10.23736/S0392-0488.16.05358-X].
Sentinel lymph node biopsy in cutaneous melanoma
DIKA, EMI;
2017
Abstract
The management of melanoma is constantly evolving. New therapies and surgical advances have changed the landscape over the last years. Since being introcuced by Dr Donald Morton, the role of sentinel lymph node has been debated. In many melanoma centres, sentinel node biopsy is not a standard of care for melanoma above 1 mm in thickness. The results of the MSLT-II trial are not available for a while and in the meantime, this procedure is offered as a prognostic indicator as it has been shown to be very useful for assessing risk of relapse. The biology of lymph node spread in melanoma is a complex field and there are many factors which influence it such as age, melanoma body site, thickness but other factors such as regression, ulceration and gender need further evaluation.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
